Rockin Robin SongFlying The Web For News.





Globe NewsWire News Distribution Service


Geneva, Switzerland and Westport, CT, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Launched today, the Alliance for Advancing Bioelectronic Medicine (AABM) is an independent network of professionals united to advance bioelectronic medicine – one of the most innovative and exciting fields in healthcare. The alliance aims to align bioelectronic medicine leaders on shared goals, facilitate cross-sector collaboration, mobilize key external audiences, and build awareness of the field overall.

“Bioelectronic medicine represents a tremendous opportunity to improve patients’ lives and change our world. However, achieving this will require much greater collaboration and awareness from a much larger and more diverse group of stakeholders,” said Kenneth L. Londoner, Founder, CEO, and Chairman of BioSig Technologies, a medical technology company that has supported creation of AABM. “We believe that the Alliance for Advancing Bioelectronic Medicine will play a much-needed role by aligning and amplifying voices in the field, winning over new allies, and driving progress that, ultimately, benefits everyone.”

The alliance brings together leaders in bioelectronic medicine: a rapidly growing field of healthcare that explores how targeted electrical signals can harness the body’s natural mechanisms to diagnose and treat a range of diseases. Its members are committed to realizing the potential of bioelectronic medicine to transform diagnosis and care for millions of people, particularly in areas of unmet need such as Parkinson’s disease, major depressive disorder, treatment-resistant epilepsy, heart arrhythmia, and chronic pain.

“The Alliance for Advancing Bioelectronic Medicine will support greater collaboration among experts across different sectors, disease areas, disciplines, and specialties,” said Samuel Asirvatham, M.D. a founding member of AABM and Vice Chair, Innovation and Medical Director, Electrophysiology Laboratory, Cardiovascular Diseases at the Mayo Clinic. “The collaboration hopes to pave the way to novel diagnostics and treatment options for patients.”

 The alliance grew out of an invitation-only roundtable in the spring of 2019, at which a distinguished group of researchers, entrepreneurs, and healthcare experts agreed on the need for an ongoing dialogue to advance a shared vision for bioelectronic medicine and a catalyst to unite the field. Since that gathering, members have developed a consensus on a shared definition, a unified narrative, and a set of tailored messages for the many groups that stand to benefit from bioelectronic medicine.

“We’ve seen impressive scientific and medical progress in bioelectronic medicine in recent years,” said Dr. Hein Heidbuchel, Professor and Chair of Cardiology, Antwerp University and President of the European Heart Rhythm Association. “But what has been missing is a compelling story that builds understanding and support for this field across a wide range of relevant audiences.”

The Alliance for Advancing Bioelectronic Medicine aims to play a unique convening role, mobilizing patients, physicians, and other stakeholders to advocate for the field, and increasing awareness among audiences that are important for the field’s growth, including policymakers, investors, media, and the general public. Its steering committee includes experts with experience at Battelle, European Heart Rhythm Association, The Feinstein Institute, Heart Rhythm Society, Imperial College London, Mayo Clinic, RAND Corporation and Sheba Medical Center. 

The alliance will be coordinated by High Lantern Group, a strategic positioning firm active in global health policy. “We see great potential for bioelectronic medicine to help serve unmet medical needs and achieve healthier societies,” said Mario Ottiglio, Managing Director at High Lantern Group. “We look forward to collaborating with this community to shape a compelling policy agenda that attracts broad support and helps accelerate the growth of this nascent industry.”

For more information, please contact:

Ms. Julie Pierce

Managing Director

High Lantern Group 

Ms. Natasha Drapeau

Executive Vice President

BioSig Technologies, Inc.


info@advancingbioelectronicmedicine.org

+1 203-409-5444, x119  

Meryl Ellingson
High Lantern Group
6263442722
mellingson@highlanterngroup.com


Posted: 2019-11-18 23:41:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



More News From This Category
Press Release: Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Mon, 07 Sep 2026 07:08:20 +0000

COPENHAGEN, Denmark, September 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an amount up to DKK 250 million in the period from September 1, 2026 to October 30, 2026. The program is executed in accordance…

Read More ...


Press Release: Willis appoints Trevor Madden as Head of Captive and Insurance Management Solutions, Asia Pacific
Mon, 07 Sep 2026 04:08:24 +0000

SINGAPORE, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Willis, a WTW business (NASDAQ: WTW), today announced the appointment of Trevor Madden as Head of Captive and Insurance Management Solutions, Asia Pacific, effective 1 November 2026.

Read More ...


Press Release: MoneySimpler Enhances AI Automated Trading With Real-Time Market Analysis
Mon, 07 Sep 2026 01:08:35 +0000

MoneySimpler has upgraded its AI-powered automated trading platform to help users manage digital asset transactions more efficiently

Read More ...


Press Release: PHH、BYAH 最後期限:領先的投資者法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Park Ha Biological Technology Co., Ltd. 投資者在對 PHH、BYAH 提出證券集體訴訟的重要截止日期前聘請律師
Sun, 06 Sep 2026 22:08:17 +0000

紐約, Sept. 07, 2026 (GLOBE NEWSWIRE) -- 事因:全球投資者權益律師事務所 Rosen Law Firm 提醒於 2024 年 12 月 27 日至 2025 年 7 月 8 日(包括首尾兩日)(下稱「集體訴訟期」)購買 Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) 證券的人士注意,首席原告的重要截止日期為 2026 年 9 月 28 日。

Read More ...


Press Release: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
Sun, 06 Sep 2026 19:08:22 +0000

NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.

Read More ...


Related Bing News Results





















Blow Us A Whistle


RobinsPost Print On Demand Refund Policy With Printify
Printify

Related Product Search/Búsqueda de productos relacionados

Amazon Logo